Inspira Technologies to Present at the Aegis Capital Corp. Virtual Conference

Inspira Technologies (Nasdaq: IINN) announced that President & CFO Joe Hayon will present at the Aegis Virtual Event on February 23, 2022, at 8:30am EST.

Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) announced that President & CFO Joe Hayon will present at the Aegis Virtual Event on February 23, 2022, at 8:30am EST. The presentation can be accessed here. Inspira focuses on innovative respiratory technology, developing the ART system to serve as an early extracorporeal support solution, potentially reducing the need for invasive ventilation. The product is still under development and has not received regulatory approval.

Argus Session date unavailable

-1.61% session move Open Argus

Details

News Market Reaction – IINN

The recorded move for IINN in the trading session of this news was -1.61%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RA'ANANA, Israel, Feb. 10, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW), a groundbreaking respiratory support technology company, today announced that Joe Hayon, Inspira's President & Chief Financial Officer will present at the Aegis Virtual Event on February 23, 2022 at 8:30am EST. The presentation can be accessed using this link here.

For more information, please visit Inspira Technologies' Investor Relations page here.  

About Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART system, a cost effective early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory patients. The ART is designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and spontaneously breathing, potentially minimizing the patient's need for invasive mechanical ventilation. The Company's product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or the CE or other required regulatory agencies.

For more information, please visit our corporate website: https://inspira-technologies.com 

For more details:

Miri Segal
Investor Relations
MS-IR LLC
+1-917-607-8654
msegal@ms-ir.com

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/inspira-technologies-to-present-at-the-aegis-capital-corp-virtual-conference-301479742.html

SOURCE Inspira Technologies

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Inspira Technologies present at the Aegis Virtual Event?

Inspira Technologies will present at the Aegis Virtual Event on February 23, 2022, at 8:30am EST.

Who is presenting for Inspira Technologies at the Aegis Virtual Event?

Joe Hayon, the President & CFO of Inspira Technologies, will present at the event.

What is the focus of Inspira Technologies' ART system?

The ART system is designed as an early extracorporeal respiratory support solution, potentially acting as an 'Artificial Lung' for patients with deteriorating respiratory conditions.

Is Inspira Technologies' ART system approved by the FDA?

No, the ART system has not yet been tested in humans and has not received FDA approval or regulatory clearance.

How can I access the presentation by Inspira Technologies?

The presentation can be accessed using this link: here.